Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 2;110(4):926–940. doi: 10.1002/cpt.2238

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Artemether‐lumefantrine dosing in different populations. The World Health Organization (WHO) endorsed treatment guidelines are based solely on a patient’s weight with adults receiving 4 tablets (80 mg artemether (AR) and 480 mg lumefantrine (LF). Young children < 15 kg receive 1 tablet of 20 mg artemether and 120 mg lumefantrine. Pharmacokinetic/pharmacodynamic (PK/PD) models have proposed that artemether‐lumefantrine dosing be extended over 5 instead of 3 days in special populations, including pregnant women, young and underweight children, as well as HIV co‐infected patients receiving efavirenz based antiretroviral therapy or other CYP450 inducers.